ArticleDiscover oncology2025
Identification and validation of a prognostic model for HER2-low breast cancer based on unfolded protein response-related genes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesHuman epidermal growth factor receptor 2 (HER2) is down-regulated in approximately 45-55% of breast cancer patients. Cancer cells activate endoplasmic reticulum stress, which is counteracted by the unfolded protein response (UPR). The objective of the present research is to assess the predictive significance of UPR-related genes and investigate their effects on the immune landscape in HER2-low breast cancer patients.
methodsThe prognostic UPR related genes in patients were identified by univariate Cox regression analysis, and the risk score model was created using LASSO Cox regression analysis. The nomogram model was built using RMS package, and the protein-protein interaction network was created via the STRING database.
resultsThrough comprehensive analysis, we identified four UPR-related genes (COPS5, DKC1, NOP56, and EIF4G1) that were significantly associated with HER2-low breast cancer prognosis. These genes were utilized to construct a robust risk score model, which effectively stratified patients into high- and low-risk groups. Patients in the high-risk group exhibited significantly worse clinical outcomes, confirming the independent prognostic value of the risk score in multivariate analysis. Furthermore, pathway enrichment analysis revealed significant suppression of immune-related signaling pathways (e.g. PI3K-AKT) in high-risk patients, alongside distinct tumor microenvironment profiles characterized by differential immune cell infiltration, altered expression of immune checkpoints, and significantly different TIDE scores, suggesting potential implications for immunotherapy response stratification.
conclusionsThe prognostic model based on UPR related genes, COPS5, DKC1, NOP56, and EIF4G1, could predict the prognosis of HER2-low breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.